

****UPDATE** AIDS Drug Assistance Program (ADAP) Formulary Update and Guidance:**

Due to rising health care insurance premiums nationwide and lack of additional Ryan White grant funding, adjustments have been made to ensure resources to the greatest number of individuals within the Florida Department of Health's funding constraints.

Starting **April 1, 2026**, Descovy will be restricted to patients with CrCl <60. The required preauthorization form can be located here: https://www.floridahealth.gov/wp-content/uploads/2026/03/Descovy-PA-Form_2026.pdf

Additionally, as of March 1, 2026, Biktarvy is no longer available on the ADAP formulary as a medication option for Ryan White Part B ADAP patients receiving direct medication assistance, however, clinically equivalent medications will still be available.

All other current ART medications will be available. We will continue to monitor formulary for cost and may have to make additional adjustments if needed.

Patients enrolled in the CVS Caremark (Retail Dispense Program) for co-pay and deductible assistance will continue to receive Biktarvy and Descovy.

Additional Information:

- When transitioning a patient to a new ART regimen, such as Tivicay plus Truvada, other Truvada-based or NRTI-based regimen in combination with integrase inhibitors, or alternative class outside of integrase inhibitors, please refer to the guidelines from [Initiation of Antiretroviral Therapy | NIH](#).
-

Patient Assistance:

Patients with CrCl <60 will be required to receive preauthorization to receive Descovy.

If your patient no longer qualifies for ADAP assistance, have them contact their case manager. They may qualify for Partnership for Prescription Assistance and for other patient assistance programs.

There are over 180 programs offered by pharmaceutical companies that provide free or low-cost drugs for individuals who cannot afford to pay for them. Each program has specific eligibility criteria and coverage. Additional resources can be found here: [Florida Health - ADAP](#).

- For patients who have questions regarding their Direct Dispense status, the Department's pharmacy benefit manager, Prime Therapeutics, can be contacted at 833-604-0925 to discuss options.
 - For any additional questions or patients who are impacted, seeking general resources and guidance, ADAP Help Desk can be contacted at 844-381-2327.
-